A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses.
Phase of Trial: Phase II/III
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Brincidofovir (Primary)
- Indications DNA virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chimerix
- 08 Sep 2014 Results published in the Media Release.
- 31 Jul 2014 Results in subset of renal transplant patients presented at the 2014 World Transplant Congress.
- 31 Jul 2014 Results in subset of patients switching from cidofovir or foscarnet presented at the 2014 World Transplant Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History